EUR 0.4
(-3.59%)
Year | Total Assets | Total Assets Growth |
---|---|---|
2023 | 50.24 Million EUR | -12.68% |
2022 | 57.54 Million EUR | -5.48% |
2021 | 60.87 Million EUR | 45.34% |
2020 | 41.88 Million EUR | 0.0% |
2019 | - EUR | 0.0% |
Year | Total Assets | Total Assets Growth |
---|---|---|
2024 Q2 | 56.42 Million EUR | 0.0% |
2024 Q1 | 56.42 Million EUR | 12.3% |
2023 FY | 50.24 Million EUR | -12.68% |
2023 Q3 | 50.24 Million EUR | -14.58% |
2023 Q1 | 58.82 Million EUR | 2.22% |
2023 Q4 | 50.24 Million EUR | 0.0% |
2023 Q2 | 58.82 Million EUR | 0.0% |
2022 Q4 | 57.54 Million EUR | 0.0% |
Name | Total Assets | Total Assets Difference |
---|---|---|
Nicox S.A. | 52.98 Million EUR | 5.164% |
European Medical Solutions | 43.75 Million EUR | -14.822% |
argenx SE | 4.11 Billion EUR | 98.778% |
BioSenic S.A. | 9.55 Million EUR | -425.62% |
Celyad Oncology SA | 16.28 Million EUR | -208.586% |
Hyloris Pharmaceuticals SA | 47.68 Million EUR | -5.375% |
Onward Medical N.V. | 43.62 Million EUR | -15.162% |
Oxurion NV | 6.55 Million EUR | -667.084% |
PHAXIAM Therapeutics S.A. | 51.3 Million EUR | 2.072% |
Financière de Tubize SA | 1.92 Billion EUR | 97.383% |
UCB SA | 15.53 Billion EUR | 99.677% |